Please upgrade your browser
In order to have the best possible experience on www.valuepartners-group.com, we recommend that you upgrade to a newer version or switch to a different browser.
Currently browsing:


Value Partners Ireland Fund ICAV –
Value Partners Health Care Fund#

Other Funds

    • Risk Disclosure
      • Value Partners Health Care Fund (the “Fund”) primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
      • The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
      • Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with Stock Connects. The Fund may also expose to RMB currency and conversion risk.
      • Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
      • The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
      • You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.

    Performance Updateas at 11-06-2024

    Performance Update

    Annual Returns

    Annual Returns

    Performance Since Launch as at 11-06-2024

    Performance Since Launch

    #The funds are sub-funds of Value Partners Ireland Fund ICAV (the “Company”). The Company is both authorized and supervised by the Central Bank of Ireland (“Central Bank”) as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011. Authorization of the Company by the Central Bank shall not constitute a warranty as to the performance of the Company and the Central Bank shall not be liable or the performance or default of the Company. The authorization of the Company is not an endorsement or guarantee of the Company by the Central Bank.

    Source: Value Partners & Morningstar

    Performance shown is NAV to NAV in denominated currency with income reinvested and net of fees. For funds/classes denominated in foreign currencies, US/HK dollar-based investors are therefore exposed to fluctuations in the currency exchange rate. All indices are for reference only. 

    Investment involves risk. Past performance is not indicative of future performance. The price of units/NAV per share can go down as well as up and is not guaranteed. Investors may not get back the full amount invested. Please refer to the relevant offering documents including the risk factors.

    +The Fund is one of the eligible collective investment schemes for the purpose of the New Capital Investment Entrant Scheme (New CIES) in Hong Kong with effect from 1 March 2024.

    Investment Objective

    The Fund aims to achieve long-term capital growth by investing primarily in equities and equity-related securities in healthcare companies including pharmaceuticals, biotechnology, healthcare services and medical technology and supplies on a worldwide basis.

    Open-ended Umbrella Investment Company

    Value Partners Ireland Fund ICAV

    Promoter and investment manager

    Value Partners Hong Kong Limited

    Depositary

    HSBC Continental Europe

    Legal status

    Authorized by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities (UCITS) pursuant to the European Communities UCITS Regulations 1

    Launch date

    02-04-2015

    Base currency

    US dollar

    Other currency class available

    AUD, AUD (hedged), CAD, CAD (hedged), Euro, Euro (hedged), GBP, GBP (hedged), HKD, NZD, NZD (hegded), RMB, RMB (hedged), SGD, SGD (hedged), USD 

    Minimum subscription

    AUD 10,000 / CAD 10,000 / EUR 10,000 / GBP 10,000 / HKD 80,000 / RMB 60,000/ SGD 10,000 / USD 10,000 / USD (Class Z) 10,000,000

    Initial subscription fee

    Up to 5% of the issue price

    Investment manager fees

    1.5% per annum

    1% per annum (for Class Z USD)

    Dealing frequency

    Daily
    Cutoff time: 11.59am Irish time

    Print

    1. Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc) is authorized and supervised by the Central Bank of Ireland (“Central Bank”). Authorization by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. Authorization of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank.
    2. Transactions for currency hedging purposes may be carried out in respect of shares in the Hedged Classes; for details on this and/or for a full list of share classes, please refer to the prospectus and the relevant fund supplement.
    +The Fund is one of the eligible collective investment schemes for the purpose of the New Capital Investment Entrant Scheme (New CIES) in Hong Kong with effect from 1 March 2024.
    
    Loading...
    Type of DocumentDateDownload
    From
    To
    Date

    Class A USD Unhedged

    Class A HKD Unhedged

    Class A SGD Unhedged

    Class A EUR Unhedged

    Class A RMB Unhedged

    Class A SGD Hedged

    • Risk Disclosure

      • Value Partners Health Care Fund (the “Fund”) primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
      • The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
      • Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with Stock Connects. The Fund may also expose to RMB currency and conversion risk.
      • Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
      • The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
      • You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.
    • Performance

      Performance Update

      Performance Update

      Annual Returns

      Annual Returns

      Performance Since Launch as at 11-06-2024

      Performance Since Launch

      #The funds are sub-funds of Value Partners Ireland Fund ICAV (the “Company”). The Company is both authorized and supervised by the Central Bank of Ireland (“Central Bank”) as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011. Authorization of the Company by the Central Bank shall not constitute a warranty as to the performance of the Company and the Central Bank shall not be liable or the performance or default of the Company. The authorization of the Company is not an endorsement or guarantee of the Company by the Central Bank.

      Source: Value Partners & Morningstar

      Performance shown is NAV to NAV in denominated currency with income reinvested and net of fees. For funds/classes denominated in foreign currencies, US/HK dollar-based investors are therefore exposed to fluctuations in the currency exchange rate. All indices are for reference only. 

      Investment involves risk. Past performance is not indicative of future performance. The price of units/NAV per share can go down as well as up and is not guaranteed. Investors may not get back the full amount invested. Please refer to the relevant offering documents including the risk factors.

      +The Fund is one of the eligible collective investment schemes for the purpose of the New Capital Investment Entrant Scheme (New CIES) in Hong Kong with effect from 1 March 2024.
    • Fund Facts

      Investment Objective

      The Fund aims to achieve long-term capital growth by investing primarily in equities and equity-related securities in healthcare companies including pharmaceuticals, biotechnology, healthcare services and medical technology and supplies on a worldwide basis.

      Open-ended Umbrella Investment Company

      Value Partners Ireland Fund ICAV

      Promoter and investment manager

      Value Partners Hong Kong Limited

      Depositary

      HSBC Continental Europe

      Legal status

      Authorized by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities (UCITS) pursuant to the European Communities UCITS Regulations 1

      Launch date

      02-04-2015

      Base currency

      US dollar

      Other currency class available

      AUD, AUD (hedged), CAD, CAD (hedged), Euro, Euro (hedged), GBP, GBP (hedged), HKD, NZD, NZD (hegded), RMB, RMB (hedged), SGD, SGD (hedged), USD 

      Minimum subscription

      AUD 10,000 / CAD 10,000 / EUR 10,000 / GBP 10,000 / HKD 80,000 / RMB 60,000/ SGD 10,000 / USD 10,000 / USD (Class Z) 10,000,000

      Initial subscription fee

      Up to 5% of the issue price

      Investment manager fees

      1.5% per annum

      1% per annum (for Class Z USD)

      Dealing frequency

      Daily
      Cutoff time: 11.59am Irish time

      Print

      1. Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc) is authorized and supervised by the Central Bank of Ireland (“Central Bank”). Authorization by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. Authorization of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank.
      2. Transactions for currency hedging purposes may be carried out in respect of shares in the Hedged Classes; for details on this and/or for a full list of share classes, please refer to the prospectus and the relevant fund supplement.
      +The Fund is one of the eligible collective investment schemes for the purpose of the New Capital Investment Entrant Scheme (New CIES) in Hong Kong with effect from 1 March 2024.
    • Documents

      
      Loading...
      Type of DocumentDateDownload
    • Historical Prices

      From
      To
      Date

      Class A USD Unhedged

      Class A HKD Unhedged

      Class A SGD Unhedged

      Class A EUR Unhedged

      Class A RMB Unhedged

      Class A SGD Hedged

      From
      To
      Date

      Class A USD Unhedged

      Class A HKD Unhedged

      Class A SGD Unhedged

      Class A EUR Unhedged

      Class A RMB Unhedged

      Class A SGD Hedged